对《利伐沙班治疗非瓣膜性心房颤动患者的卒中及大出血临床危险因素：EXPAND研究亚组分析》的勘误
Correction to: Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.
作者信息
Sakuma Ichiro, Uchiyama Shinichiro, Atarashi Hirotsugu, Inoue Hiroshi, Kitazono Takanari, Yamashita Takeshi, Shimizu Wataru, Ikeda Takanori, Kamouchi Masahiro, Kaikita Koichi, Fukuda Koji, Origasa Hideki, Shimokawa Hiroaki
机构信息
Cardiovascular Medicine, Hokko Memorial Clinic, Sapporo, Hokkaido, Japan.
Center for Brain and Cerebral Vessels, Sanno Hospital and Sanno Medical Center, International University of Health and Welfare, 8-5-35 Akasaka, Minato-ku, Tokyo, Japan.
出版信息
Heart Vessels. 2019 Nov;34(11):1852-1857. doi: 10.1007/s00380-019-01479-x.
Abstract
In the original publication of the article, the Figure 2b and the Tables 2 and 3 were published incorrectly. The corrected figure and tables are provided below.
摘要
在该文章的原始发表中，图2b以及表2和表3发表有误。更正后的图表如下所示。
相似文献
1
Correction to: Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.对《利伐沙班治疗非瓣膜性心房颤动患者的卒中及大出血临床危险因素：EXPAND研究亚组分析》的勘误
Heart Vessels. 2019 Nov;34(11):1852-1857. doi: 10.1007/s00380-019-01479-x.
2
Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.利伐沙班治疗非瓣膜性心房颤动患者时卒中及大出血的临床危险因素：EXPAND研究亚组分析
Heart Vessels. 2019 Nov;34(11):1839-1851. doi: 10.1007/s00380-019-01425-x. Epub 2019 May 24.
3
Primary and secondary prevention of stroke and systemic embolism with rivaroxaban in patients with non-valvular atrial fibrillation : Sub-analysis of the EXPAND Study.利伐沙班用于非瓣膜性心房颤动患者卒中及全身性栓塞的一级和二级预防：EXPAND研究的亚组分析
Heart Vessels. 2019 Jan;34(1):141-150. doi: 10.1007/s00380-018-1219-0. Epub 2018 Jul 6.
4
The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.EXPAND 研究：利伐沙班在非瓣膜性心房颤动日本患者中的疗效和安全性。
Int J Cardiol. 2018 May 1;258:126-132. doi: 10.1016/j.ijcard.2018.01.141. Epub 2018 Feb 3.
5
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.在美国医疗保险人群中，与华法林相比，起始使用阿哌沙班、达比加群或利伐沙班的非瓣膜性心房颤动患者发生中风/全身性栓塞、大出血及相关费用的风险。
Curr Med Res Opin. 2017 Sep;33(9):1595-1604. doi: 10.1080/03007995.2017.1345729. Epub 2017 Jul 11.
6
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.非瓣膜性心房颤动患者应用阿哌沙班、达比加群、利伐沙班或华法林起始抗凝治疗的大出血风险的真实世界比较：倾向评分匹配分析。
Thromb Haemost. 2016 Oct 28;116(5):975-986. doi: 10.1160/TH16-05-0403. Epub 2016 Aug 19.
7
Effectiveness and safety of rivaroxaban vs warfarin in people with non-valvular atrial fibrillation and diabetes: an administrative claims database analysis.利伐沙班与华法林在非瓣膜性心房颤动合并糖尿病患者中的有效性和安全性：行政索赔数据库分析。
Diabet Med. 2018 Aug;35(8):1105-1110. doi: 10.1111/dme.13648. Epub 2018 May 3.
8
Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan.在美国一项健康计划中，对接受口服抗凝剂治疗的非瓣膜性心房颤动患者的全因住院、中风和大出血导致的住院情况及费用进行的真实世界比较。
J Med Econ. 2018 Mar;21(3):244-253. doi: 10.1080/13696998.2017.1394866. Epub 2017 Nov 20.
9
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.利伐沙班与华法林治疗外周动脉疾病合并非瓣膜性心房颤动患者的疗效和安全性：来自 ROCKET AF 的观察。
Eur Heart J. 2014 Jan;35(4):242-9. doi: 10.1093/eurheartj/eht492. Epub 2013 Dec 2.
10
Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.EXPAND研究的设计与基线特征：在日本非瓣膜性心房颤动患者全国队列中评估Xa因子抑制剂利伐沙班预防卒中及全身性栓塞的有效性和安全性
Tohoku J Exp Med. 2016 Dec;240(4):259-268. doi: 10.1620/tjem.240.259.
引用本文的文献
1
Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation.利伐沙班治疗老年日本非瓣膜性心房颤动患者的真实世界结局
Heart Vessels. 2020 Mar;35(3):399-408. doi: 10.1007/s00380-019-01487-x. Epub 2019 Sep 6.
Zotero 插件